Home Trials Current Trials TEXAIS: A Multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

TEXAIS: A Multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

E-mail Print PDF

Lead PI: Professor Chris Bladin

Status: Site Selection

No. of Patients Currently Recruited: 0                               No. of Patients Required: 528

Phase 2, multicentre, prospective, randomised, open label, blinded end-point (PROBE) trial with pre-planned adaptive sample size re-estimation. 10 sites anticipated to randomise 528 (1:1 ratio) patients by 2019. Primary Hypothesis: Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke will improve neurological outcome as measured by >8 point improvement in NIHSS stroke disability score (or NIHSS 0-1) at 7 days.

Trial URL:

https://clinicaltrials.gov/ct2/show/NCT03287076

Last Updated ( Wednesday, 10 January 2018 13:00 )  

Registered Charity



Latest news

Top Views